[Form 4] Health Catalyst, Inc Insider Trading Activity
Ross David Coy, Chief Technology & Product Officer of Health Catalyst, Inc. (HCAT), reported a non-discretionary sale of 3,360 shares of common stock on 09/02/2025 at an average price of $3.3627 per share. The filing states the sale was a sell-to-cover transaction to satisfy tax withholding obligations tied to vesting restricted stock units and was not a discretionary trade. After the transaction the reporting person beneficially owns 204,219 shares, held directly. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/04/2025.
Ross David Coy, Chief Technology & Product Officer di Health Catalyst, Inc. (HCAT), ha comunicato una vendita non discrezionale di 3.360 azioni ordinarie in data 09/02/2025 a un prezzo medio di $3.3627 per azione. La dichiarazione specifica che la transazione è stata una operazione di sell-to-cover per coprire il pagamento delle imposte legate al vesting di restricted stock units e non un trade discrezionale. Dopo la transazione, la persona segnalante detiene beneficiariamente 204.219 azioni, possedute direttamente. Il Modulo 4 è stato firmato per procura da un avvocato il 09/04/2025.
Ross David Coy, Chief Technology & Product Officer de Health Catalyst, Inc. (HCAT), informó una venta no discrecional de 3.360 acciones ordinarias el 09/02/2025 a un precio medio de $3.3627 por acción. El informe indica que la operación fue un sell-to-cover para cubrir retenciones fiscales relacionadas con el vesting de restricted stock units y no una transacción discrecional. Tras la operación, la persona informante posee beneficiariamente 204.219 acciones, en poder directo. El Formulario 4 fue firmado por un apoderado en nombre de la persona informante el 09/04/2025.
Ross David Coy, Health Catalyst, Inc.(HCAT) 최고기술·제품책임자(Chief Technology & Product Officer)는 2025년 09월 02일에 보통주 3,360주를 주당 평균 $3.3627에 비재량적(non-discretionary)으로 매도했다고 보고했습니다. 제출서에는 해당 매각이 제한주(RSU) 가속에 따른 세금 원천징수 의무를 충당하기 위한 sell-to-cover 거래였으며 재량적 거래가 아니었다고 명시되어 있습니다. 거래 후 보고인은 직접 보유 형태로 혜택상 204,219주를 소유하고 있습니다. Form 4는 2025년 09월 04일에 대리인이 보고인을 대신해 서명했습니다.
Ross David Coy, Chief Technology & Product Officer de Health Catalyst, Inc. (HCAT), a déclaré une cession non discrétionnaire de 3 360 actions ordinaires le 09/02/2025 au prix moyen de 3,3627 $ par action. Le dépôt précise que la vente était une opération de sell-to-cover visant à couvrir les retenues fiscales liées au vesting d'unités d'actions restreintes et n'était pas une transaction discrétionnaire. Après l'opération, la personne déclarante détient, à titre bénéficiaire, 204 219 actions, détenues directement. Le formulaire 4 a été signé par un mandataire au nom de la personne déclarante le 09/04/2025.
Ross David Coy, Chief Technology & Product Officer von Health Catalyst, Inc. (HCAT), meldete am 09/02/2025 einen nicht-diskretionären Verkauf von 3.360 Stammaktien zu einem Durchschnittspreis von $3.3627 pro Aktie. In der Meldung heißt es, der Verkauf sei ein sell-to-cover-Geschäft zur Erfüllung von Steuerabzugsverpflichtungen im Zusammenhang mit dem Vesting von Restricted Stock Units gewesen und kein diskretionärer Handel. Nach der Transaktion besitzt die meldende Person wirtschaftlich 204.219 Aktien, direkt gehalten. Das Formular 4 wurde am 09/04/2025 von einem Bevollmächtigten im Namen der meldenden Person unterzeichnet.
- Form discloses the sale was a sell-to-cover tied to RSU tax withholding, clarifying the transaction was non-discretionary
- Reporting shows continued substantial ownership: 204,219 shares remain beneficially owned directly
- None.
Insights
TL;DR: Routine sell-to-cover for RSU tax withholding; minimal market impact and reflects compensation vesting, not a directional sell.
The transaction is explicitly described as a mandated sell-to-cover tied to tax withholding on vested restricted stock units, indicating it is part of routine equity compensation administration rather than an active disposition decision by the insider. The volume of 3,360 shares relative to the reporting person's remaining direct holdings of 204,219 shares suggests the trade is immaterial to ownership concentration and unlikely to influence HCAT's market price.
TL;DR: Proper disclosure of a non-discretionary tax-related sale; governance procedures appear followed.
The Form 4 discloses the relationship (Officer) and the nature of the sale (sell-to-cover for RSU withholding). The filing by a single reporting person and signature by an attorney-in-fact indicate administrative compliance with Section 16 reporting requirements. No evidence in the filing of trading pursuant to a 10b5-1 plan or other discretionary transactions.
Ross David Coy, Chief Technology & Product Officer di Health Catalyst, Inc. (HCAT), ha comunicato una vendita non discrezionale di 3.360 azioni ordinarie in data 09/02/2025 a un prezzo medio di $3.3627 per azione. La dichiarazione specifica che la transazione è stata una operazione di sell-to-cover per coprire il pagamento delle imposte legate al vesting di restricted stock units e non un trade discrezionale. Dopo la transazione, la persona segnalante detiene beneficiariamente 204.219 azioni, possedute direttamente. Il Modulo 4 è stato firmato per procura da un avvocato il 09/04/2025.
Ross David Coy, Chief Technology & Product Officer de Health Catalyst, Inc. (HCAT), informó una venta no discrecional de 3.360 acciones ordinarias el 09/02/2025 a un precio medio de $3.3627 por acción. El informe indica que la operación fue un sell-to-cover para cubrir retenciones fiscales relacionadas con el vesting de restricted stock units y no una transacción discrecional. Tras la operación, la persona informante posee beneficiariamente 204.219 acciones, en poder directo. El Formulario 4 fue firmado por un apoderado en nombre de la persona informante el 09/04/2025.
Ross David Coy, Health Catalyst, Inc.(HCAT) 최고기술·제품책임자(Chief Technology & Product Officer)는 2025년 09월 02일에 보통주 3,360주를 주당 평균 $3.3627에 비재량적(non-discretionary)으로 매도했다고 보고했습니다. 제출서에는 해당 매각이 제한주(RSU) 가속에 따른 세금 원천징수 의무를 충당하기 위한 sell-to-cover 거래였으며 재량적 거래가 아니었다고 명시되어 있습니다. 거래 후 보고인은 직접 보유 형태로 혜택상 204,219주를 소유하고 있습니다. Form 4는 2025년 09월 04일에 대리인이 보고인을 대신해 서명했습니다.
Ross David Coy, Chief Technology & Product Officer de Health Catalyst, Inc. (HCAT), a déclaré une cession non discrétionnaire de 3 360 actions ordinaires le 09/02/2025 au prix moyen de 3,3627 $ par action. Le dépôt précise que la vente était une opération de sell-to-cover visant à couvrir les retenues fiscales liées au vesting d'unités d'actions restreintes et n'était pas une transaction discrétionnaire. Après l'opération, la personne déclarante détient, à titre bénéficiaire, 204 219 actions, détenues directement. Le formulaire 4 a été signé par un mandataire au nom de la personne déclarante le 09/04/2025.
Ross David Coy, Chief Technology & Product Officer von Health Catalyst, Inc. (HCAT), meldete am 09/02/2025 einen nicht-diskretionären Verkauf von 3.360 Stammaktien zu einem Durchschnittspreis von $3.3627 pro Aktie. In der Meldung heißt es, der Verkauf sei ein sell-to-cover-Geschäft zur Erfüllung von Steuerabzugsverpflichtungen im Zusammenhang mit dem Vesting von Restricted Stock Units gewesen und kein diskretionärer Handel. Nach der Transaktion besitzt die meldende Person wirtschaftlich 204.219 Aktien, direkt gehalten. Das Formular 4 wurde am 09/04/2025 von einem Bevollmächtigten im Namen der meldenden Person unterzeichnet.
FAQ
What did HCAT insider Ross David Coy report on Form 4?
Is the sale by Ross Coy a discretionary trade or part of an equity plan?
How many HCAT shares does Ross Coy own after the reported transaction?
When was the Form 4 signed and who signed it?
What price was received for the sold shares?
